Integration of Recurrent Somatic Mutations with Clinical Outcomes: A Pooled Analysis of 1049 Patients with Clear Cell Renal Cell Carcinoma
Brandon J. Manley(Moffitt Cancer Center), A. Ari Hakimi(Penn State Milton S. Hershey Medical Center), Victor E. Reuter(Memorial Sloan Kettering Cancer Center), Darren R. Feldman(Memorial Sloan Kettering Cancer Center), Almedina Redzematovic(Memorial Sloan Kettering Cancer Center), James J. Hsieh(Memorial Sloan Kettering Cancer Center), Teppei Morikawa(Dana-Farber Cancer Institute), Paul Russo(Memorial Sloan Kettering Cancer Center), Seishi Ogawa(Keio University), Yusuke Sato(Tokai University), Maria E. Arcila(Memorial Sloan Kettering Cancer Center), Emily C. Zabor(Cleveland Clinic), Jozefina Casuscelli(LMU Klinikum), Robert J. Motzer(Memorial Sloan Kettering Cancer Center), Daniel Tennenbaum(Memorial Sloan Kettering Cancer Center), Haruki Kume(The University of Tokyo), Yukio Homma(University of Tokyo Hospital), Nicole Benfante, Jonathan Coleman(Memorial Sloan Kettering Cancer Center), Martin H. Voss(Memorial Sloan Kettering Cancer Center), Maria F. Becerra(Memorial Sloan Kettering Cancer Center), Masashi Fukayama(The University of Tokyo)
Cited by 51
Related Papers
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
|New England Journal of Medicine|2018|4.6k
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.8k
OncoKB: A Precision Oncology Knowledge Base
|JCO Precision Oncology|2017|2.7k
Clinical-grade computational pathology using weakly supervised deep learning on whole slide images
|Nature Medicine|2019|2.6k